These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 25572783)

  • 1. Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activity.
    Porta C; Giglione P; Liguigli W; Paglino C
    Future Oncol; 2015; 11(1):39-50. PubMed ID: 25572783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma.
    Kim KB; Chesney J; Robinson D; Gardner H; Shi MM; Kirkwood JM
    Clin Cancer Res; 2011 Dec; 17(23):7451-61. PubMed ID: 21976540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma.
    Angevin E; Lopez-Martin JA; Lin CC; Gschwend JE; Harzstark A; Castellano D; Soria JC; Sen P; Chang J; Shi M; Kay A; Escudier B
    Clin Cancer Res; 2013 Mar; 19(5):1257-68. PubMed ID: 23339124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II results of Dovitinib (TKI258) in patients with metastatic renal cell cancer.
    Escudier B; Grünwald V; Ravaud A; Ou YC; Castellano D; Lin CC; Gschwend JE; Harzstark A; Beall S; Pirotta N; Squires M; Shi M; Angevin E
    Clin Cancer Res; 2014 Jun; 20(11):3012-22. PubMed ID: 24691021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disposition and metabolism of 14C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors.
    Dubbelman AC; Upthagrove A; Beijnen JH; Marchetti S; Tan E; Krone K; Anand S; Schellens JH
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):653-63. PubMed ID: 23010851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
    André F; Bachelot T; Campone M; Dalenc F; Perez-Garcia JM; Hurvitz SA; Turner N; Rugo H; Smith JW; Deudon S; Shi M; Zhang Y; Kay A; Porta DG; Yovine A; Baselga J
    Clin Cancer Res; 2013 Jul; 19(13):3693-702. PubMed ID: 23658459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer.
    Lim SM; Chung WY; Nam KH; Kang SW; Lim JY; Kim HG; Shin SH; Sun JM; Kim SG; Kim JH; Kang CW; Kim HR; Cho BC
    Eur J Cancer; 2015 Aug; 51(12):1588-95. PubMed ID: 26070683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors.
    Sarantopoulos J; Goel S; Chung V; Munster P; Pant S; Patel MR; Infante J; Tawbi H; Becerra C; Bruce J; Kabbinavar F; Lockhart AC; Tan E; Yang S; Carlson G; Scott JW; Sharma S
    Cancer Chemother Pharmacol; 2016 Nov; 78(5):921-927. PubMed ID: 27681579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A drug-drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors.
    de Weger VA; Goel S; von Moos R; Schellens JHM; Mach N; Tan E; Anand S; Scott JW; Lassen U
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):73-80. PubMed ID: 29101463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetic/pharmacodynamic modeling to assist dosing schedule selection for dovitinib.
    Wang X; Kay A; Anak O; Angevin E; Escudier B; Zhou W; Feng Y; Dugan M; Schran H
    J Clin Pharmacol; 2013 Jan; 53(1):14-20. PubMed ID: 23400739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of dovitinib (TKI258) in recurrent glioblastoma.
    Schäfer N; Gielen GH; Kebir S; Wieland A; Till A; Mack F; Schaub C; Tzaridis T; Reinartz R; Niessen M; Fimmers R; Simon M; Coch C; Fuhrmann C; Herrlinger U; Scheffler B; Glas M
    J Cancer Res Clin Oncol; 2016 Jul; 142(7):1581-9. PubMed ID: 27100354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma.
    Kim HR; Kang HN; Shim HS; Kim EY; Kim J; Kim DJ; Lee JG; Lee CY; Hong MH; Kim SM; Kim H; Pyo KH; Yun MR; Park HJ; Han JY; Youn HA; Ahn MJ; Paik S; Kim TM; Cho BC
    Ann Oncol; 2017 Jun; 28(6):1250-1259. PubMed ID: 28460066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma.
    Milowsky MI; Dittrich C; Durán I; Jagdev S; Millard FE; Sweeney CJ; Bajorin D; Cerbone L; Quinn DI; Stadler WM; Rosenberg JE; Lochheed M; Sen P; Squires M; Shi M; Sternberg CN
    Eur J Cancer; 2014 Dec; 50(18):3145-52. PubMed ID: 25457633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, crossover phase 1 study to assess the effects of formulation (capsule vs tablet) and meal consumption on the bioavailability of dovitinib (TKI258).
    Infante JR; Ramanathan RK; George D; Tan E; Quinlan M; Liu A; Scott JW; Sharma S
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):729-37. PubMed ID: 25648347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [FGF/FGFR blockade: New insights in endometrial cancer].
    Flippot R; Vignot S
    Bull Cancer; 2015 Dec; 102(12):964-5. PubMed ID: 26617116
    [No Abstract]   [Full Text] [Related]  

  • 16. The effect of formulation and food consumption on the bioavailability of dovitinib (TKI258) in patients with advanced solid tumors.
    Sharma S; Britten CD; Mortimer J; Kulkarni S; Quinlan M; Liu A; Scott JW; George D
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):867-74. PubMed ID: 25193431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models.
    Bello E; Colella G; Scarlato V; Oliva P; Berndt A; Valbusa G; Serra SC; D'Incalci M; Cavalletti E; Giavazzi R; Damia G; Camboni G
    Cancer Res; 2011 Feb; 71(4):1396-405. PubMed ID: 21212416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study.
    Konecny GE; Finkler N; Garcia AA; Lorusso D; Lee PS; Rocconi RP; Fong PC; Squires M; Mishra K; Upalawanna A; Wang Y; Kristeleit R
    Lancet Oncol; 2015 Jun; 16(6):686-94. PubMed ID: 25981814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dovitinib: rationale, preclinical and early clinical data in urothelial carcinoma of the bladder.
    Mazzola CR; Siddiqui KM; Billia M; Chin J
    Expert Opin Investig Drugs; 2014 Nov; 23(11):1553-62. PubMed ID: 25284004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective activity over a constitutively active RET-variant of the oral multikinase inhibitor dovitinib: results of the CNIO-BR002 phase I-trial.
    Quintela-Fandino M; Bueno MJ; Lombardia L; Gil M; Gonzalez-Martin A; Marquez R; Bratos R; Guerra J; Tan E; Lopez A; Colomer R; Salazar R
    Mol Oncol; 2014 Dec; 8(8):1719-28. PubMed ID: 25103625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.